Role of Beclin1 expression in patients with hepatocellular carcinoma: a meta-analysis
Authors Liang C, Li W, Ge H, Zhang KT, Li GM, Wu J
Received 15 September 2017
Accepted for publication 13 March 2018
Published 27 April 2018 Volume 2018:11 Pages 2387—2397
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr XuYu Yang
Chaojie Liang,1,* Wei Li,1,* Hua Ge,1 Kaitong Zhang,2 Guangming Li,1 Jixiang Wu1
1Department of General Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, People’s Republic of China; 2Department of Tumor Center, Beijing Tongren Hospital, Capital Medical University, Beijing, People’s Republic of China
*These authors contributed equally to this work
Background and aim: Beclin1 has been reported as a vital marker for a number of malignant tumors. However, the role of Beclin1 in hepatocellular carcinoma (HCC) remains inconclusive. Thus, we conducted a meta-analysis to assess the correlation between Beclin1 and its clinicopathological and prognostic values in HCC.
Methods: PubMed, Cochrane Library, Web of Science, EMBASE, Chinese CNKI, and Chinese WanFang databases were searched for published articles on Beclin1 expression in hepatocellular tissues. Standard-compliant articles were screened using the Newcastle–Ottawa Scale for strict quality control of the literature. The correlation of Beclin1 expression with the clinicopathological features and survival outcomes was analyzed. Pooled odds ratios and hazard ratios with 95% confidence intervals were calculated using STATA14.2.
Results: Eleven articles with 1,279 patients were included in this meta-analysis. Positive Beclin1 expression was found to be correlated with alpha fetoprotein, liver cirrhosis, and vascular invasion, but not with gender, age, HBsAg, size of tumor, number of tumors, differentiation, and TNM stage. Positive Beclin1 expression was also associated with favorable 5-year overall survival and disease-free survival rates.
Conclusion: Our meta-analysis indicated that positive Beclin1 expression was negatively related to alpha fetoprotein, liver cirrhosis, and vascular invasion in HCC. Beclin1 could be used as a prognostic biomarker for HCC.
Keywords: Beclin1, hepatocellular carcinoma, prognosis, meta-analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]